Zidovudine (ZDV or AZT)

2 DOSAGE & ADMINISTRATION, Treatment of HIV-1 infection: Adults: Recommended oral dosage is 300 mg twice a day with other antiretroviral agents.

Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.

Zidovudine tablets are contraindicated in patients who have had a potentially life-threatening hypersensitivity reaction (e.g., anaphylaxis, Stevens-Johnson syndrome) to any of the components of the formulations. Hypersensitivity to zidovudine or any of the components (e.g., anaphylaxis, Stevens-Johnson syndrome).

Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.

See boxed warning for information about the following: hematologic toxicity, myopathy, and lactic acidosis and severe hepatomegaly, Exacerbation of anemia has been reported in HIV-1/HCV co-infected patients receiving ribavirin and zidovudine. Coadministration of ribavirin and zidovudine is not advised., Hepatic decompensation, (some fatal), has occurred in HIV-1/HCV co-infected patients receiving combination antiretroviral therapy and interferon alfa with/without ribavirin.

Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.

The following adverse reactions are discussed in greater detail in other sections of the labeling: Hematologic toxicity, including neutropenia and anemia., Symptomatic myopathy., Lactic acidosis and severe hepatomegaly with steatosis., Hepatic decompensation in patients co-infected with HIV-1 and hepatitis C.

Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.

23 products from 11 makers in the NepalDoc medicine catalog use this generic:

Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.

Store at 20° to 25° C (68° to 77°F).

Storage information from the U.S. FDA-approved label.